Infliximab Treatment Does Not Induce Organ-specific or Nonorgan-specific Autoantibodies Other than Antinuclear and Anti-Double-Stranded DNA Autoantibodies in Crohnʼs Disease

Abstract

The humoral response induced by infliximab was restricted to ANA and anti-dsDNA autoantibodies, which persist for up to 1 year of follow-up. We confirmed the significant prevalence of such autoantibodies induced by infliximab in CD, but they are not generally associated with clinical signs of autoimmunity.

Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease

“…A small study including 35 infliximab-treated CD patients and 32 CD patients without infliximab treatment showed in 14.3% of CD patients ANA titers of 1:160 before infliximab treatment which increased to 45.7% after 24 months of infliximab treatment. 27 This was very similar to the 44.4% ANA-positive patients found in our study. In the control population 18.8% of the CD patients were ANApositive.…”

“…In the control population 18.8% of the CD patients were ANApositive. 27 The same study showed dsDNA antibodies in one patient (3%) at baseline and in 35% after 1 year of infliximab treatment, while none of the control patients (without infliximab treatment) became dsDNA-positive. 27 In another small study including 36 CD patients treated with infliximab, 22.2% were ANA-positive at baseline.…”

“…27 The same study showed dsDNA antibodies in one patient (3%) at baseline and in 35% after 1 year of infliximab treatment, while none of the control patients (without infliximab treatment) became dsDNA-positive. 27 In another small study including 36 CD patients treated with infliximab, 22.2% were ANA-positive at baseline. 28 After 6 weeks of infliximab treatment, an additional 16.7% became ANA-positive (¼ 38.9% ANA-positive patients).…”

Management of Crohn's Disease in Adults

“…A signicant percentage of patients treated with anti-TNF therapy develop positive anti-nuclear antibodies and a smaller proportion develop antibodies to double-stranded DNA (148,150) . e development of symptomatic disease (i.e., drug-induced lupus) is distinctly unusual and no patient has developed renal or central nervous system involvement (155) .…”

Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet’s disease with infliximab

“…It was reported that development of ANA and anti-dsDNA antibodies is seen during the course of anti-TNF- therapy in patients with some autoimmune diseases such as rheumatoid arthritis [32][33][34], psoriasis [35], Crohn's disease [36], and BD [22]. In the present study, 75.0% of the patients converted to ANA-positive during the course of IFX therapy and positive ANA titres (1: 80) had been detected in one patient on study enrolment.…”